Latent tuberculosis diagnosis in rheumatoid arthritis;Abordagem diagnóstica da tuberculose latente na artrite reumatóide

Revista Brasileira de Reumatologia

Volumn 47, Issue 6, 2007, Pages 424-430

  Marques, Claáudia Diniz Lopes ^a,b   Duarte, Angela Luzia Branco Pinto ^b   Cavalcanti, Fernando de Souza ^b   Freese de Carvalho, Eduardo Maia ^a   Gomes, Yara de Miranda ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Anti TNF; Rheumatoid arthritis; Tuberculosis

Indexed keywords

BCG VACCINE; TUMOR NECROSIS FACTOR ANTIBODY;

CELLULAR IMMUNITY; CORRELATION ANALYSIS; CROSS REACTION; CYTOKINE PRODUCTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; IMMUNOASSAY; IMMUNOSTIMULATION; IN VITRO STUDY; INTERMETHOD COMPARISON; MICROORGANISM; MYCOBACTERIUM TUBERCULOSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN ANALYSIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; TUBERCULIN TEST; TUBERCULOSIS; VIRUS REACTIVATION;

EID: 51549119934     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0482-50042007000600006     Document Type: Review

References (42)

1. Keane J: TNT-Blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 44: 714-20, 2005.
2. Stenger S: Immunological control of tuberculosis: role of tumor necrosis factor and more. Ann Rheum Dis 64: iv24-iv28, 2005.
3. Tufariello JM, Chan J, Flynn JL: Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis 3: 578-90, 2003.
4. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO: Granulomatosis infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38: 1261-5, 2004.
5. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD: Treatment of rheumatoid arthritis with tumor necrosis factor inibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48: 2122-7, 2003.
6. Ormerod LP, Milburn HJ, Gillespie S, Ledingham J, Rampton D: BTS recommendations for assessing risk and managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNFα treatment. Thorax 60: 800-5, 2005.
7. Pai M: Alternatives to the tuberculin skin test: interferon-γ assays in the diagnosis of Mycobacterium tuberculosis infection. Indian J Med Micr 23(3): 151-8, 2005.
8. Whalen CC: Diagnosis of Latent Tuberculosis Infection. Measure for Measure. JAMA 293: 2785-7, 2005.
9. Corbett EL, Watt CJ, Walker N, et al.: The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163: 1009-21, 2003.
10. Frieden TF, Sterling TR, Munsiff SS, et al.: Tuberculosis. Lancet 362: 887-9, 2003.
11. Andersen, P, Munk ME, Pollock JM, Doherty TM: Specific immune-based diagnosis of tuberculosis. Lancet 23: 1099-104, 2000.
12. Blumberg HM, Leonard MK, Jasmer RM: Update on the Treatment of Tuberculosis and Latent Tuberculosis Infection. JAMA 293: 2776-84, 2005.
13. Silva Jr JB. Tuberculose: Guia de Vigilância Epidemiológica. J Bras Pneumol 30: S57-S85, 2004.
14. Furin JJ, Johnson JL: Recent advances in the diagnosis and management of tuberculosis. Curr Op Pulm Med 11: 189-94, 2005.
15. CDC - Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Moth Mortal Wkly Rep 49: 1-5, 2000.
16. Pai M, Gockhal EK, Joshi B, et al.: Mycobacterium tuberculosis Infection in Health Care Workers in Rural India: Comparison of a Whole-Blood Interferon [gamma] Assay With Tuberculin Skin Testing. JAMA 293: 2746-55, 2005.
17. Provenzano G, Ferrante MC, Simon G: TB screening and anti-TNF α treatment. Thorax 60: 612-5, 2005.
18. Mangini C, Melo FAF: Artrite reumatóide, terapia imunossupressora c tuberculose. Rev Bras Reumatol 43: XI-XV, 2003.
19. Cush JJ, Matteson EL: Hotline 2001 FDA Advisory Committee Review Safety of TNF Inhibitors. Disponível em: http://www.rheumatology.org/ publications/hotline/0901tnf.asp. Acessado em: 2/11/2005.
20. Mariette X, Salmon D, and group ratio: French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 62: 791, 2003.
21. Panayi G, Corrigal V, Pitzalis C: Pathogenesis of rheumatoid arthritis. The role of cells and others beasts. Rheum Dis Clin North Am 161: 221-47, 2001.
22. Corrigal, VM, Garyfallos A, Panayi GS: The relative proportions of secreted interleukin-2 and interleukin-10 determine the magnitude of rheumatoid arthritis T-cell proliferations to the recall antigen tuberculin purified protein derivative. Rheumatology 38: 1203-7, 1999.
23. Emery P, Panayi G, Symmons D, Brown G: Mechanisms of depressed delayed-type hypersensitivity in rheumatoid arthritis: the role of protein energy malnutrition. Ann Rheum Dis 43: 430-4, 1984.
24. Kingsley GH, Pitzalis C, Panay GS: Abnormal lymphocyte reactivity to self-major histocompatibility antigens in rheumatoid arthritis. J Rheumatol 14: 667-73, 1987.
25. + T cells in the blood predicts the in vivo response to PPD. Tuberculosis 87: 202-11, 2007.
26. Ehrenstein MR, Evans JG, Singh A, et al.: Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNF-a Therapy. JEM 200: 277-85, 2004.
27. Ponce de León D, Acevedo-Vásquez E, Sánchez-Torres A, et al.: Attenuated response to purified protein derivate in patients with rheumatoid artritis: study in a population with high prevalence of tuberculosis. Ann Rheum Dis 64: 1360-1, 2005.
28. Köker IH, Pamuk ÖN, Karlikaya C, Tunçbilek N, Çakir N: A low prevalence of purified protein derivative test positivity in Turkish patients with rheumatoid arthritis. Association with clinical features and HRCT findings. Clin Exp Rheumatol 25: 54-9, 2007.
29. Meier T, Eulenbruch HP, Wrighton-Smith P, Enders G, Regnath T: Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice. Eur J Clin Microbiol Infec Dis 24: 529-36, 2005.
30. Pittius NCG, Gamieldien J, Hide W, et al.: The ESAT-6 gene cluster of Mycobacterium tuberculosis and other high G+C Gram-positive bacteria. Genome Biology 2, RESEARCH0044, 2001. Epub 2001 Sep 19.
31. Barnes PF: Diagnosis latent tuberculosis infection: turning glitter to gold. Am J Resp Crit Care Med 170: 5-6, 2004.
32. Lalvani A: Spotting latent infection: the path to better tuberculosis control. Thorax 58: 916-8, 2003.
33. Mori T, Sakatani M, Yamagishi F, et al.: Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 170: 59-64, 2004.
34. Kang YA, Lee HW, Yoon HI, et al.: Discrepancy Between the Tuberculin Skin Test and the Whole-Blood Interferon-γ Assay for the Diagnosis of Latent Tuberculosis Infection in an Intermediate Tuberculosis-Burden Country. JAMA 293: 2756-61, 2005.
35. Ewer K, Deeks J, Alvarez L, et al.: Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 361: 1168-73, 2005.
36. Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P: Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 170: 65-9, 2004.
37. Kang YA, Lee HW, Yoon HI, et al.: Discrepancy between the tuberculin skin test and the whole-blood interferon. JAMA 293: 2756-61, 2005.
38. Chapman AL, Munkanta M., Wilkinson KA, et al.: Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T-cells. AIDS 16: 2285-93, 2002.
39. NICE: National Institute for Health and Clinical Excellence - Guideline no. 33. Disponível em: http://guidance.nice.org.uk/CG33/guidance/ pdf/Engtish. Acessado em: 1/7/2007.
40. Centers for Disease Control and Prevention. Guidelines for the investigation of contacts of persons with infectious tuberculosis; recommendations from the National Tuberculosis Controllers Association and CDC, and Guidelines for using the QuantiFERON®-TB Gold test for detecting Mycobactcrium tuberculosis infection, United States. MMWR 2005; 54 (No. RR-15). Disponível em: http://www.cdc.gov/mmwr/ PDF/rr/rr5415.pdf. Acessado em: 1/7/2007.
41. Lee JY, Choi HJ, Park IN, et al.: Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 28: 24-30, 2006.
42. Takahashi H, Shigehara K, Yamamoto M, et al.: Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration. Rheumatol Int 27(12): 1143-8, 2007.